Scarica l'app Stockscreener
1.63
3.55%
-0.06
Dopo l'orario di chiusura:
1.64
0.01
+0.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.69
Aprire:
$1.69
Volume 24 ore:
1.16M
Relative Volume:
0.56
Capitalizzazione di mercato:
$244.32M
Reddito:
$42.17M
Utile/perdita netta:
$-183.12M
Rapporto P/E:
-1.1194
EPS:
-1.4562
Flusso di cassa netto:
$-138.51M
1 W Prestazione:
-10.44%
1M Prestazione:
+1.24%
6M Prestazione:
+26.36%
1 anno Prestazione:
+83.02%
Intervallo 1D:
$1.605
$1.76
Intervallo di 1 settimana:
$1.605
$2.0598
Portata 52W:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Nome
Coherus Oncology Inc
Settore
Industria
Telefono
(650) 649-3530
Indirizzo
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.63 | 244.32M | 42.17M | -183.12M | -138.51M | -1.4562 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Oppenheimer | Outperform |
| 2025-09-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-16 | Downgrade | UBS | Buy → Neutral |
| 2023-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2023-07-24 | Iniziato | Citigroup | Buy |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2023-03-28 | Aggiornamento | UBS | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Neutral |
| 2022-03-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Iniziato | BofA Securities | Neutral |
| 2020-04-17 | Iniziato | SunTrust | Buy |
| 2019-08-13 | Iniziato | Mizuho | Buy |
| 2019-08-02 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-02 | Reiterato | Maxim Group | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-09 | Reiterato | Maxim Group | Buy |
| 2017-08-08 | Reiterato | JP Morgan | Overweight |
| 2017-06-13 | Reiterato | Maxim Group | Buy |
| 2017-05-05 | Iniziato | BMO Capital Markets | Outperform |
| 2016-10-19 | Iniziato | Robert W. Baird | Outperform |
| 2016-09-07 | Iniziato | Maxim Group | Buy |
| 2016-07-27 | Iniziato | Citigroup | Buy |
| 2016-01-20 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf. - Yahoo Finance
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - Sahm
Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates - MSN
Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift By Investing.com - Investing.com Canada
Coherus Oncology Doubles LOQTORZI Revenue in 2025, Advances Oncology Pipeline and Significantly Reduces Debt 1 - Minichart
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform By Investing.com - Investing.com South Africa
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform - Investing.com
Coherus Oncology, Inc. 2025 Annual Report – LOQTORZI Sales Growth, Pipeline Advances, and Strategic Shift to Immuno-Oncology - Minichart
Coherus BioSciences Q4 2025 earnings preview - MSN
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus Oncology Q4 2025 Earnings Call Transcript - MarketBeat
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: St - GuruFocus
Coherus Oncology (CHRS) Sees Strong Growth with LOQTORZI - GuruFocus
Coherus Oncology Reports Q4 Earnings Loss - National Today
Coherus Oncology Q4 Earnings Call Highlights - MarketBeat
CHRS: LOQTORZI sales doubled, debt slashed, and key oncology trials advance toward 2026 data - TradingView
CHRS: LOQTORZI revenue doubled, debt slashed, and pipeline advances set up major 2026 milestones - TradingView
CHRS Q4 Revenue Falls Short but Strategic Shift Shows Promise - GuruFocus
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual ProfitNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Coherus Oncology: Fourth Quarter Financial Results Overview - Bitget
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Coherus Oncology: Q4 Earnings Snapshot - Barchart
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect - GuruFocus
Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts - National Today
Coherus Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coherus BioSciences's Earnings Outlook - Benzinga
How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks - Yahoo Finance
Coherus BioSciences at TD Cowen Conference: Strategic Oncology Shift - Investing.com
CHRS: Strong oncology focus, robust pipeline, and accelerating LOQTORZI sales drive future growth - TradingView
CHRS: Rapid oncology transformation, strong LOQTORZI growth, and promising pipeline assets drive outlook - TradingView
Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow - Quiver Quantitative
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewswire
March 9 Coherus Oncology webcast on full-year and Q4 2025 results - Stock Titan
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday - MarketBeat
CHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Hepatocellular Carcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 90+ Key Companies | DelveInsight - StreetInsider
Hepatocellular Carcinoma Clinical Trial Pipeline Shows - openPR.com
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 (NASDAQ:CHRS) - Seeking Alpha
Coherus Oncology announces proposed public offering of common stock - MSN
How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS) - Yahoo Finance
Coherus closes $50.1 million public offering of common stock - Investing.com India
Coherus Biosciences Completes $47 Million Equity Offering - TipRanks
Coherus closes $50.1 million public offering of common stock By Investing.com - Investing.com UK
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock - The Manila Times
Oncology biotech Coherus raises $50M for LOQTORZI and clinical programs - Stock Titan
Coherus Oncology (NASDAQ: CHRS) raises $47M through common stock offering - Stock Titan
Coherus Oncology Inc Azioni (CHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):